Michele
Schoonmaker

Subject Matter Expert

About Michele

We are thrilled to announce that Michele Schoonmaker, PhD, has joined the Zensights team as a Subject Matter Expert. Michele is a nationally recognized leader in market access and government affairs for advanced diagnostics, with more than 25 years of success shaping how innovative tests are regulated, reimbursed, and adopted in clinical practice. Trained as a molecular biologist, she spent nearly a decade at the National Institutes of Health while completing her doctorate in health services research and genetic policy at Johns Hopkins. Her dissertation—focused on how health insurers make coverage decisions for genetic tests—set the foundation for a career built on one central question: how do we move cutting-edge science into real-world patient care in a way that payers, regulators, and policymakers can all support?

Early in her industry career, Michele served as Director of Medical Reimbursement at Vysis (now Abbott Molecular), where she helped pioneer dedicated reimbursement strategy for genetic and molecular cytogenetic tests at a time when most diagnostic companies had no such function. She then joined FDA’s Center for Devices and Radiological Health as a biologist reviewing diagnostic applications and supporting immunology advisory panels and guidance development. From there, she moved to the Congressional Research Service as a Specialist in Genetics, providing bipartisan, bicameral analysis to Congress on topics such as the regulation of medical devices, pharmacogenomics, personalized medicine, and Alzheimer’s policy—experience that sharpened her ability to translate complex science into objective, actionable policy options.

In 2005, Michele joined Cepheid and spent 17 years building and leading its Government Affairs function as the company grew from a $25M life sciences player into a multi-billion-dollar global diagnostics leader. As SVP of Government Affairs, she led a transatlantic team across four tightly connected pillars: health economics and reimbursement, government affairs and policy, professional relations, and external advocacy. While Cepheid was best known for its infectious disease portfolio, Michele also supported the company’s expanding oncology offerings—work that further deepened her insight into how high-complexity diagnostics are regulated, paid for, and integrated into clinical practice. She is particularly skilled at coalition-building—aligning medical societies, laboratory associations, patient groups, and policymakers around practical solutions that expand appropriate access to high-value testing.

Today, as owner of Michele Schoonmaker LLC and a Zensights Subject Matter Expert, Michele focuses on helping diagnostic and biopharmaceutical companies design evidence-driven market access strategies for novel and often first-in-class tests. She works with startups and established organizations alike to assess the market landscape, define regulatory and reimbursement pathways, and build integrated roadmaps for companion diagnostics, next-generation sequencing panels, and other precision medicine tools across oncology, cardiovascular disease, neurology, mental health, and rare disease. Companies turn to Michele when they need a 360-degree view—from FDA to CMS to Capitol Hill—of what it will take to secure coverage, payment, and real-world uptake for state-of-the-art diagnostic technologies. We couldn’t be more excited to bring Michele and her exceptional expertise onto the team.

Connect with Michele on Linkedin: